Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) kicked off on Friday, down -4.11% from the previous trading day, before settling in for the closing price of $13.87. Over the past 52 weeks, TEVA has traded in a range of $7.09-$14.47.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -2.68%. While this was happening, its average annual earnings per share was recorded -6.18%. With a float of $1.12 billion, this company’s outstanding shares have now reached $1.12 billion.
Considering the fact that the conglomerate employs 37226 people, you should pay attention to its efficiency factor.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Teva- Pharmaceutical Industries Ltd. ADR is 0.01%, while institutional ownership is 52.40%. The most recent insider transaction that took place on Mar 06 ’24, was worth 1,048,119. In this transaction EVP, Chief Financial Officer of this company sold 77,550 shares at a rate of $13.52, taking the stock ownership to the 203,691 shares. Before that another transaction happened on Mar 05 ’24, when Company’s EVP, International Markets sold 100,000 for $13.52, making the entire transaction worth $1,352,090. This insider now owns 382,590 shares in total.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 3.58 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -6.18% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.60% during the next five years compared to 26.63% growth over the previous five years of trading.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Trading Performance Indicators
Take a look at Teva- Pharmaceutical Industries Ltd. ADR’s (TEVA) current performance indicators. Last quarter, stock had a quick ratio of 0.69. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.94. Likewise, its price to free cash flow for the trailing twelve months is 6.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.48, a number that is poised to hit 0.52 in the next quarter and is forecasted to reach 2.63 in one year’s time.
Technical Analysis of Teva- Pharmaceutical Industries Ltd. ADR (TEVA)
Compared to the last year’s volume of 10.77 million, its volume of 9.59 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 22.67%. Additionally, its Average True Range was 0.37.
During the past 100 days, Teva- Pharmaceutical Industries Ltd. ADR’s (TEVA) raw stochastic average was set at 79.33%, which indicates a significant increase from 16.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.88% in the past 14 days, which was lower than the 30.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.36, while its 200-day Moving Average is $10.53. Nevertheless, the first resistance level for the watch stands at $13.64 in the near term. At $13.99, the stock is likely to face the second major resistance level. The third major resistance level sits at $14.27. If the price goes on to break the first support level at $13.01, it is likely to go to the next support level at $12.73. Should the price break the second support level, the third support level stands at $12.38.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Key Stats
The company with the Market Capitalisation of 14.91 billion has total of 1,121,094K Shares Outstanding. Its annual sales at the moment are 15,846 M in contrast with the sum of -559,000 K annual income. Company’s last quarter sales were recorded 4,457 M and last quarter income was 429,000 K.
